MedTrace Logo

Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter

NCT00421421 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 276

Last updated 2007-11-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of dutasteride at reducing relapse rates of Acute Urinary Retention (AUR), including reduction in surgical intervention for benign prostatic hyperplasia (BPH), in patients who receive a 6 month treatment of dutasteride (0.5mg once daily) following a single episode of AUR followed by successful Trial Without Catheter compared with placebo.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DRUG

Dutasteride

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials, BSc MBBS · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00421421 on ClinicalTrials.gov